Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PTH/Calcium · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | PTH 100 mcg and 700 mg calcium |
| 2 | EXPERIMENTAL | PTH 100 mcg and placebo |
| 3 | PLACEBO_COMPARATOR | Placebo and 700 mg calcium |
| Name | Type | Description |
|---|---|---|
| PTH/Calcium | DRUG | PTH(1-84) subcutaneous injection and calcium 700 mg oral |
| PTH/placebo | DRUG | PTH (1-84) injected subcutaneously and placebo provided orally |
| placebo | DRUG | Placebo injected subcutaneously and 700 mg calcium orally |
Inclusion Criteria: * Women who are capable of understanding and giving written, voluntary informed consent before the clinical study screening visit * Women with the ability to self-administer a daily injection or having a designee who will give the injections * Women who are postmenopausal with a...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Precision BioSciences, Inc. | DTIL | 1 | N/A | Undisclosed |
| SI-BONE, Inc. | SIBN | 1 | - | Undisclosed |
PTH/Calcium is an investigational small molecule being studied for the treatment of osteoporosis in postmenopausal women. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
PTH/Calcium is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with osteoporosis.
PTH/Calcium is in Phase 3 clinical development. It is an investigational drug and has not yet received regulatory approval. The Phase 3 trial has been completed, and the drug remains under evaluation for the treatment of osteoporosis.
PTH/Calcium has one completed Phase 3 clinical trial registered under NCT00172172, titled "Calcium Supplementation in Postmenopausal Women." The trial enrolled 374 participants with osteoporosis across the United States, Argentina, and Mexico.
PTH/Calcium is a drug being studied for osteoporosis, and its Phase 3 trial is titled "Calcium Supplementation in Postmenopausal Women." The trial evaluates the drug in postmenopausal women aged 45 years and older with osteoporosis.